Longboard to Discuss PACIFIC Trial Results for Bexicaserin in DEEs

Longboard Pharmaceuticals, a company centered on developing innovative treatments for neurological disorders, has announced the topline results from its PACIFIC Study. This study was a Phase 1b/2a clinical trial that assessed bexicaserin (LP352), a promising 5-HT2C receptor superagonist, in individuals with Developmental and Epileptic Encephalopathies (DEEs). The drug is being developed with a focus on its potential to be a leading treatment option with a unique profile that does not affect 5-HT2B and 5-HT2A receptor subtypes.

The company is set to discuss these results in a conference call scheduled for January 2nd, providing an opportunity for stockholders and other interested parties to gain insights into the study's findings. The call will be accessible through the company's website, with a replay available for a period of 30 days post-event.

Bexicaserin is an oral medication designed to treat seizures associated with DEEs. It is intended to modulate GABA, thereby reducing the hyperexcitability observed in seizures. The drug's unique chemistry and specificity for the 5-HT2C receptor subtype are believed to offer advantages over existing treatments in terms of safety and efficacy.

The PACIFIC Study was a double-blind, placebo-controlled trial involving 52 participants aged between 12 and 65 years. It was conducted across 34 sites in the U.S. and Australia. Participants underwent a dose titration phase followed by a 60-day maintenance period on the highest tolerated dose. After this period, participants were given the option to enroll in a 52-week open-label extension program. The primary measure of efficacy was the median percent change in motor seizure frequency over a 75-day treatment period.

Longboard Pharmaceuticals is in the clinical stage of development, with a portfolio of product candidates aimed at specific G protein-coupled receptors (GPCRs). The company's research is built on over two decades of GPCR studies. In addition to bexicaserin, Longboard is also developing LP659, a next-generation modulator for rare neuroinflammatory conditions, which is currently in a Phase 1 clinical trial.